FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286266912> ?p ?o ?g. }

• W4286266912 endingPage "103760" @default.
• W4286266912 startingPage "103760" @default.
• W4286266912 abstract "A growing number of regimens have been approved as first-line treatments for patients with advanced epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer. However, the optimal regimen has not been determined, especially for patients with different clinicopathological characteristics. Therefore, we performed this meta-analysis to compare the efficacy and safety of first-line treatments for patients with EGFR-mutated NSCLC based on clinicopathological characteristics, thereby providing evidence for individual patient clinical decision-making.The PubMed, Embase, Cochrane Library databases, and abstracts of ASCO, ESMO, and WCLC were searched from inception to 3 June 2021 to identify eligible randomized controlled trials (RCTs). The outcomes of progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and grade 3 or higher adverse events (≥3AEs) were compared and ranked based on various clinicopathological characteristics among 14 regimens by network meta-analysis (NMA) and the surface under the cumulative ranking curve (SUCRA), respectively.25 RCTs were included, with a total of 6965 patients and 14 treatment regimens. The primary endpoint of all RCTs was PFS, and OS, ORR, and ≥3AEs were secondary endpoints. Regarding overall patients, the most distinct PFS benefit was observed in osimertinib (OSI), with the fewest ≥3AEs, whereas gefitinib plus pemetrexed-based chemotherapy (GEF+PB) provided the greatest benefit for OS. When considering EGFR mutation type, aumolertinib (AUM) and GEF+PB could be the optimal regimens in terms of PFS for patients with EGFR 19DEL and EGFR 21L858R, respectively. Notably, the efficacy of the 14 regimens for PFS varied across clinicopathological characteristics, with GEP+PB ranking first in Eastern Cooperative Oncology Group performance status (ECOG PS)= 1, Asian, age＜65 and smoking subgroups, with AUM ranking first in ECOG PS= 0 and female subgroups, with ICO+PB ranking first in age ≥65 and no smoking subgroups, and with AFA+CET ranking first in the male subgroup. In terms of brain metastases, third-generation EGFR-TKI showed obvious superiority, with AUM and OSI optimally prolonging PFS in patients with and without brain metastases, respectively. In addition, GEF+PB is a superior alternative, ranking second in terms of PFS regardless of the presence of brain metastases.OSI and GEF+PB were the most two effective first-line regimens for overall patients, ranking first in PFS and OS, respectively. GEF+PB ranked first in terms of PFS in subgroups of EGFR 21L858R, ECOG PS= 1, Asian, age <65, and smoking. Meanwhile, AUM in subgroups of EGFR 19DEL, ECOG PS= 0, female, brain metastasis, OSI in the subgroup of without brain metastasis, ICO+PB in no smoking subgroup, and AFA+CET in male subgroup were the best options as for their evident superiority in PFS." @default.
• W4286266912 created "2022-07-21" @default.
• W4286266912 creator A5021846453 @default.
• W4286266912 creator A5023531951 @default.
• W4286266912 creator A5040730790 @default.
• W4286266912 creator A5041500202 @default.
• W4286266912 creator A5049723273 @default.
• W4286266912 creator A5052663273 @default.
• W4286266912 creator A5071785205 @default.
• W4286266912 creator A5074302789 @default.
• W4286266912 creator A5082739478 @default.
• W4286266912 date "2022-09-01" @default.
• W4286266912 modified "2023-10-01" @default.
• W4286266912 title "Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: A systematic review and network meta-analysis" @default.
• W4286266912 cites W1617328014 @default.
• W4286266912 cites W1888498899 @default.
• W4286266912 cites W1902576439 @default.
• W4286266912 cites W1935885922 @default.
• W4286266912 cites W1966713566 @default.
• W4286266912 cites W1980497534 @default.
• W4286266912 cites W1989734503 @default.
• W4286266912 cites W2010065353 @default.
• W4286266912 cites W2010699829 @default.
• W4286266912 cites W2066107570 @default.
• W4286266912 cites W2075535893 @default.
• W4286266912 cites W2088540000 @default.
• W4286266912 cites W2111662961 @default.
• W4286266912 cites W2125435699 @default.
• W4286266912 cites W2127357802 @default.
• W4286266912 cites W2133149289 @default.
• W4286266912 cites W2136601558 @default.
• W4286266912 cites W2144625636 @default.
• W4286266912 cites W2151090489 @default.
• W4286266912 cites W2166399931 @default.
• W4286266912 cites W2168554121 @default.
• W4286266912 cites W2170830310 @default.
• W4286266912 cites W2171139285 @default.
• W4286266912 cites W2210071992 @default.
• W4286266912 cites W2299729500 @default.
• W4286266912 cites W2302258098 @default.
• W4286266912 cites W2339311613 @default.
• W4286266912 cites W2414722525 @default.
• W4286266912 cites W2461623951 @default.
• W4286266912 cites W2466033276 @default.
• W4286266912 cites W2494292000 @default.
• W4286266912 cites W2502310207 @default.
• W4286266912 cites W2507541911 @default.
• W4286266912 cites W2518488558 @default.
• W4286266912 cites W2558428915 @default.
• W4286266912 cites W2559748686 @default.
• W4286266912 cites W2565077351 @default.
• W4286266912 cites W2607954371 @default.
• W4286266912 cites W2618435741 @default.
• W4286266912 cites W2619919786 @default.
• W4286266912 cites W2734501152 @default.
• W4286266912 cites W2747505649 @default.
• W4286266912 cites W2760639821 @default.
• W4286266912 cites W2761020910 @default.
• W4286266912 cites W2767275374 @default.
• W4286266912 cites W2770828094 @default.
• W4286266912 cites W2784371446 @default.
• W4286266912 cites W2792821195 @default.
• W4286266912 cites W2794883050 @default.
• W4286266912 cites W2797780288 @default.
• W4286266912 cites W2804899966 @default.
• W4286266912 cites W2887416920 @default.
• W4286266912 cites W2890155867 @default.
• W4286266912 cites W2898102822 @default.
• W4286266912 cites W2900712986 @default.
• W4286266912 cites W2909222524 @default.
• W4286266912 cites W2937223370 @default.
• W4286266912 cites W2967398721 @default.
• W4286266912 cites W2968754080 @default.
• W4286266912 cites W2972291278 @default.
• W4286266912 cites W2977016055 @default.
• W4286266912 cites W2977860844 @default.
• W4286266912 cites W2978677918 @default.
• W4286266912 cites W2979271184 @default.
• W4286266912 cites W2985704506 @default.
• W4286266912 cites W2987053327 @default.
• W4286266912 cites W3015470279 @default.
• W4286266912 cites W3036359387 @default.
• W4286266912 cites W3087079946 @default.
• W4286266912 cites W3091781059 @default.
• W4286266912 cites W3112025484 @default.
• W4286266912 cites W3128870202 @default.
• W4286266912 cites W3144478369 @default.
• W4286266912 cites W3153271425 @default.
• W4286266912 cites W3191778845 @default.
• W4286266912 cites W4200084736 @default.
• W4286266912 cites W4205501618 @default.
• W4286266912 cites W4213133535 @default.
• W4286266912 cites W4252867417 @default.
• W4286266912 doi "https://doi.org/10.1016/j.critrevonc.2022.103760" @default.
• W4286266912 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35870763" @default.
• W4286266912 hasPublicationYear "2022" @default.
• W4286266912 type Work @default.
• W4286266912 citedByCount "4" @default.

• next